Urology
Volume 68, Issue 2, Supplement , Pages 3-8, August 2006

Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

  • Linda Brubaker

      Affiliations

    • Departments of Obstetrics, Gynecology, and Urology, Loyola University Medical Center, Maywood, Illinois, USA
    • Corresponding Author InformationReprint requests: Linda Brubaker, MD, MS, Departments of Obstetrics, Gynecology, and Urology, Loyola University Medical Center, 2160 South First Avenue, Building 103, Room 1004D, Maywood, Illinois 60153.
    • Linda Brubaker receives research funding from Q-Med, Pfizer Inc, and Allergan and receives consultant/speaker honoraria from Q-Med, Novartis, Pfizer Inc, and Astellas.
  • ,
  • Christopher Chapple

      Affiliations

    • Department of Urology Research, Royal Hallamshire Hospital, Sheffield, United Kingdom
    • Christopher Chapple is a scientific consultant to Pfizer Inc, Astellas, Novartis, Schwarz, Q-Med, Tanabe, and Allergan; and receives funding from Pfizer, and Allergan.
  • ,
  • Karin S. Coyne

      Affiliations

    • Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland, USA
    • Karin S. Coyne is a consultant to Pfizer Inc.
  • ,
  • Zoe Kopp

      Affiliations

    • Pfizer Inc, New York, New York, USA
    • Zoe Kopp is an employee of Pfizer Inc.

Abstract 

Overactive bladder (OAB) is a condition defined by its symptoms—urinary urgency with or without urgency urinary incontinence and often with frequency and nocturia. As such, determining the efficacy of OAB treatments using objective measures, such as urodynamic testing, can be difficult. A better means of gauging treatment efficacy for symptom-based conditions is through the use of patient-reported outcomes (PROs). With PROs, clinicians can gain insight into how a treatment affects a patient’s symptoms and whether improvement in symptoms has a positive effect from the patient’s perspective. PROs are increasingly being included as end points in clinical trials, including those of antimuscarinic drugs for OAB. Consequently, clinicians should become familiar with the most commonly used instruments. We provide an overview of instruments used to assess symptoms, health-related quality of life, and treatment satisfaction in patients with OAB and discuss how PROs can be incorporated into clinical trial protocols.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0090-4295(06)00773-4

doi:10.1016/j.urology.2006.05.045

Urology
Volume 68, Issue 2, Supplement , Pages 3-8, August 2006